

The new process for European Health Technology Assessment (HTA) will be applied for cancer and advanced therapy medicinal products as of January 2025. While the date is near, there is still uncertainty in various areas of how the new process will work.
Previous guidance left unanswered questions regarding
The recent publication of the draft Joint Clinical Assessment (JCA) for medicinal product Implementing Act (AI) brought clarity in some of these areas. This Insight Brief explores what has changed in the IA on JCA, what has not been addressed, and how to prepare for 2025 and beyond.